Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®

An inactivated split-virion trivalent influenza vaccine (IIV3; Vaxigrip®, Sanofi Pasteur) has been available globally since 1968. Here, we describe the results of an open-label, post-licensure trial (EudraCT no. 2014-005078-12) to confirm the immunogenicity and safety of the Southern Hemisphere 2015...

Descripción completa

Detalles Bibliográficos
Autores principales: Latreille-Barbier, Mathilde, Rouzier, Regine, Astruc, Beatrice, Lavis, Nathalie, Donazzolo, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703369/
https://www.ncbi.nlm.nih.gov/pubmed/28937844
http://dx.doi.org/10.1080/21645515.2017.1363944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703369/
https://www.ncbi.nlm.nih.gov/pubmed/28937844
http://dx.doi.org/10.1080/21645515.2017.1363944

Ejemplares similares